Actively Recruiting
Implementation of Indocyanine Green to Identify Sentinel Lymph Nodes During Surgery for Breast Cancer
Led by Isabelle Henskens · Updated on 2026-01-12
1760
Participants Needed
7
Research Sites
67 weeks
Total Duration
On this page
Sponsors
I
Isabelle Henskens
Lead Sponsor
C
Canisius-Wilhelmina Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn how to successfully introduce a new method for finding the sentinel lymph node during breast cancer surgery into routine hospital care. The method uses a dye called indocyanine green (ICG) and a special camera to see the lymph node. The sentinel lymph node is the first lymph node that cancer is likely to spread to. In the Netherlands, about 1 in 7 women develops breast cancer. Finding out whether cancer has spread to the lymph nodes is important for planning treatment and predicting outcomes. The current standard method for sentinel lymph node biopsy (SLNB) uses a radioactive tracer called radioisotope technetium-labeled (99mTc)-nanocolloid. While accurate, this method has several drawbacks: it exposes patients to radioactivity, requires an extra hospital visit or travel to another hospital due to limited nuclear medicine facilities, and is not sustainable. Surgeries using 99mTc can only take place on certain days due to logistical issues, and the signal from 99mTc can be disturbed by the tumor marker placed in the breast. ICG works as well as 99mTc for SLNB and offers several advantages: it is given during surgery (no extra visit needed), produces no radiation, and reduces costs. However, it is still not widely used in the Netherlands because hospitals may not be familiar with it or unsure how to make the switch. This study will introduce ICG step-by-step in several Dutch hospitals and evaluate how to make the change as smooth and effective as possible. It will take place in three stages: I) SLNB with 99mTc only (current practice); II) SLNB with both 99mTc and ICG (transition phase); III) SLNB with ICG only (full implementation). All study procedures take place during planned surgery, with no extra hospital visits. After surgery, participants will receive a short questionnaire (10-15 minutes) to share their experiences with the procedure. Their feedback, combined with input from healthcare providers, will help researchers develop a uniform medical protocol, an implementation guide, and educational materials for surgeons and surgical trainees. The aim is to make ICG widely available across the Netherlands, ensuring that care is less burdensome, more sustainable, and more cost-effective, while keeping treatment accessible in local hospitals.
CONDITIONS
Official Title
Implementation of Indocyanine Green to Identify Sentinel Lymph Nodes During Surgery for Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients 18 years old or older
- Diagnosis of ductal carcinoma in situ (DCIS) or invasive breast cancer confirmed by biopsy
- Clinically node-negative status confirmed by preoperative axillary ultrasound
- Planned breast cancer surgery with sentinel lymph node biopsy via axillary incision
You will not qualify if you...
- Undergoing combined MARI procedure
- Known allergy to indocyanine green (ICG), intravenous contrast, or iodine
- History of axillary lymph node dissection
- Diagnosis of hyperthyroidism or thyroid cancer
- Pregnancy or breastfeeding
- Lack of written informed consent according to ICH/GCP and national regulations
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Noordwest Ziekenhuisgroep
Alkmaar, Netherlands
Actively Recruiting
2
Ziekenhuisgroep Twente
Hengelo, Netherlands
Actively Recruiting
3
Spaarne Gasthuis
Hoofddorp, Netherlands
Actively Recruiting
4
Dijklander Ziekenhuis
Hoorn, Netherlands
Actively Recruiting
5
Alrijne Hospital
Leiden, Netherlands
Actively Recruiting
6
Canisius Wilhelmina Ziekenhuis
Nijmegen, Netherlands
Actively Recruiting
7
Diakonessenhuis
Utrecht, Netherlands
Actively Recruiting
Research Team
I
Isabelle Henskens, MD
CONTACT
A
Annemiek Doeksen, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
DIAGNOSTIC
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here